Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Identifieur interne : 001B47 ( Istex/Curation ); précédent : 001B46; suivant : 001B48Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Auteurs : O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Y. Agid [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-07.
English descriptors
Abstract
Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia. We assessed, in a pilot randomised placebo‐controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha‐2 antagonist, on motor parkinsonian disability and L‐DOPA‐induced dyskinesia following an acute oral challenge of L‐DOPA in 18 patients with Parkinson's disease. The severity of L‐DOPA‐induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L‐DOPA. These results suggest that blocking alpha‐2 receptors in patients with Parkinson's disease might improve L‐DOPA‐induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long‐term management of dyskinetic patients with Parkinson's disease. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1143
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B47
Links to Exploration step
ISTEX:D45B693FEB760DA50DF70021526CB4914873B8E7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Peyro Aint Paul, H" sort="Peyro Aint Paul, H" uniqKey="Peyro Aint Paul H" first="H." last="Peyro-Saint Paul">H. Peyro-Saint Paul</name><affiliation wicri:level="1"><mods:affiliation>Institut de recherche Pierre Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de recherche Pierre Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Brefel Ourbon, C" sort="Brefel Ourbon, C" uniqKey="Brefel Ourbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D45B693FEB760DA50DF70021526CB4914873B8E7</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1143</idno><idno type="url">https://api.istex.fr/document/D45B693FEB760DA50DF70021526CB4914873B8E7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B47</idno><idno type="wicri:Area/Istex/Curation">001B47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Peyro Aint Paul, H" sort="Peyro Aint Paul, H" uniqKey="Peyro Aint Paul H" first="H." last="Peyro-Saint Paul">H. Peyro-Saint Paul</name><affiliation wicri:level="1"><mods:affiliation>Institut de recherche Pierre Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de recherche Pierre Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Brefel Ourbon, C" sort="Brefel Ourbon, C" uniqKey="Brefel Ourbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="708">708</biblScope><biblScope unit="page" to="713">713</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D45B693FEB760DA50DF70021526CB4914873B8E7</idno><idno type="DOI">10.1002/mds.1143</idno><idno type="ArticleID">MDS1143</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐DOPA, dyskinesia</term><term>Parkinson's disease</term><term>idazoxan</term><term>α2 receptors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia. We assessed, in a pilot randomised placebo‐controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha‐2 antagonist, on motor parkinsonian disability and L‐DOPA‐induced dyskinesia following an acute oral challenge of L‐DOPA in 18 patients with Parkinson's disease. The severity of L‐DOPA‐induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L‐DOPA. These results suggest that blocking alpha‐2 receptors in patients with Parkinson's disease might improve L‐DOPA‐induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long‐term management of dyskinetic patients with Parkinson's disease. © 2001 Movement Disorder Society.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001B47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:D45B693FEB760DA50DF70021526CB4914873B8E7
|texte= Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |